On August 5, Insulet fell 11.46% in pre-market trading, trading at $145.25/share, with turnover of $1.83 million. The decline coincided with the release of the company's Q2 fiscal report amid ongoing product safety concerns.

Insulet reported Q2 adjusted EPS of $1.66, beating the consensus estimate of $1.45 by 14.48%, and representing a 41.88% year-over-year increase from $1.17 per share. Revenue of $801.7 million also surpassed the $787.228 million estimate. Despite the headline beat, shares declined sharply in pre-market trading.

The earnings release comes against a backdrop of sustained product safety headwinds. In July, the FDA classified a recall of certain Omnipod pods as Class I — its most serious category — after identifying a cannula defect that could impair insulin delivery, with 24 serious injuries reported. Earlier filings disclosed 476 serious injury cases linked to specific Omnipod 5 units. Multiple analysts had already cut price targets between April and February, with Rothschild downgrading the stock to Neutral with a $220 target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)